Bill
Bill > HR7640
US HR7640
US HR7640To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
summary
Introduced
05/03/2022
05/03/2022
In Committee
05/03/2022
05/03/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as ‘‘orphan drugs’’).
AI Summary
This bill aims to reauthorize a program of grants and contracts for the development of "orphan drugs" - drugs used to treat rare diseases and conditions - under the Orphan Drug Act. Specifically, it proposes to extend the authorized funding period for this program from 2018-2022 to 2023-2027.
Committee Categories
Business and Industry
Sponsors (2)
Last Action
Referred to the House Committee on Energy and Commerce. (on 05/03/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/house-bill/7640/all-info |
| BillText | https://www.congress.gov/117/bills/hr7640/BILLS-117hr7640ih.pdf |
| Bill | https://www.congress.gov/117/bills/hr7640/BILLS-117hr7640ih.pdf.pdf |
Loading...